

Monoclonal Anti-Influenza A Virus H3 Hemagglutinin (HA) Stalk Domain, Clone FF1.H6.H6 (AX-LAH3) (produced *in vitro*)

Catalog No. NR-50555

For research use only. Not for human use.

Contributor:

Alex Ramirez, Head, Department of Immunology, iQur Ltd., London, United Kingdom

Manufacturer:

BEI Resources

Product Description:

Antibody Class: IgG1κ

Mouse monoclonal antibody was prepared against the long alpha helix (LAH) domain of the influenza virus H3 hemagglutinin (HA) stalk protein incorporated into a synthetically prepared chimeric influenza H3 virus-like particle, a proprietary influenza vaccine candidate. The antibody was purified from clone FF1.H6.H6 hybridoma supernatant using protein G affinity chromatography. The B cell hybridoma was generated by the fusion of mouse myeloma cells with splenocytes from immunized BALB/c mice. The antibody recognizes influenza hemagglutinin stalk domain from all H3 strains.^{1,2,3}

Material Provided:

Each vial of NR-50555 contains approximately 100 µL of purified monoclonal antibody in PBS. The concentration, expressed as mg per mL, is shown on the Certificate of Analysis.

Packaging/Storage:

NR-50555 was packaged aseptically in screw-capped plastic vials and is provided frozen on dry ice. The product should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:

NR-50555 is functional in western blots, immunoprecipitation, flow cytometry, immunocytochemistry and ELISA.¹

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Influenza A Virus H3 Hemagglutinin (HA) Stalk Domain, Clone FF1.H6.H6 (AX-LAH3) (produced *in vitro*), NR-50555."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in](#)

[Microbiological and Biomedical Laboratories](#). 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Ramirez, A., Personal Communication.
2. Ramirez, A., et al. "A Virus-Like Particle Vaccine Candidate for Influenza A Virus Based on Multiple Conserved Antigens Presented on Hepatitis B Tandem Core Particles." *Vaccine* 36 (2018): 873-880. PubMed: 29306508.
3. Kazakis, A., et al. "Production and Purification of Chimeric HBc Virus-Like Particles Carrying Influenza Virus LAH Domain as Vaccine Candidates." *BMC Biotechnol.* 17 (2017): 79. PubMed: 29126399.

ATCC® is a trademark of the American Type Culture Collection.

